Delivering the next generation of precision medicine

Delivering the Next Generation of Precision Medicine.

About us

We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies. Drawing on the innovations born and bred at MIT and Harvard, coupled with thought leadership defining clinical trajectories, we are transforming disease management across hematology, cardiology, neurology and cancer.


Semiconductor technology has empowered information society and transformed the healthcare industry. Its characteristics of miniaturization, precision and cost-effectiveness give birth to high- sensitivity, high-throughput and highly-integrative bioassays, a central pillar to precisely understand biology for personalized treatment.

Vast amounts of data are generated by the wide deployment of high-throughput assays. Processed by recent AI algorithms, deeper understanding arises from the complex multi-parameter space, revealing novel biomarkers for the system biology problems central to complicated disease conditions. The incorporation of cutting-edge data analytics is essential to the early diagnosis and intervention emphasized by precision medicine.

Product Pipeline

  • Coagulation

    Coagulopathies in acute settings, following trauma and highly invasive procedures, are multifactorial. Bedside monitoring that can account for the complexities of acute coagulopathy along with fast turnaround time is invaluable to enable individualized treatment. Despite this clear BILLION-DOLLAR unmet medical need of bedside monitoring, traditional coagulation diagnostics monitor specific drugs and blood products and in addition, measure specific coagulation pathways. Therefore, they do not adequately address this need. Diagnosis in pediatric patients is further compounded by the constraint for minimal blood volume and increased biological variability due to heterogeneous developmental stages and disease presentations. Atantares’ vision is to develop the first point-of-care integrated platform consolidating major coagulation assays including platelet function test, clotting times, and viscoelasticity, with microfluidics and semiconductor technology. These are state-of-the-art technologies that redefine information society, which are characteristics of integration, precision, miniaturization, high sensitivity, and cost-effectiveness. On the device level, high automation and whole blood assay permit ease-of-use and eliminate time-consuming sample preparation, which are key requirements for diagnostic instruments in acute settings (ER/OR/ICU).

  • Digital Immunoassay

    Proteins are one of the essential components of our bodies and quantifying protein level (predominantly using immunoassays) allows characterizing biological processes and detecting malfunctions. While commonly adopted in clinical diagnostics and scientific research, conventional immunoassays have limited ability to measure protein biomarkers of low concentration with short turnaround time. On the other hand, the concentration of many important proteins is very low. For example, cytokines, a group of proteins closed related to immune response, are in low pg/ml level. Scientists need to be able to measure small amount of proteins to understand molecular signaling at single cell level. Additionally, early diagnostics and precise drug dosing demands ultrasensitive immunoassays. To address those problems, we are developing an ultrasensitive digital immunoassays which is hundreds to thousands more sensitive than traditional assays.

  • CART Companion Diagnostics

    Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treatment of hematological tumors. There have already been three commercial products and hundreds of ongoing clinical trials. However, CAR T-cell therapy faces challenges including severe toxicities. After infusion of CAR T-cell product, increases in systemic cytokine levels have been observed in patients, reflecting the robust interactions of CAR T cells with cancer cells. One-quarter to two-thirds of the patients experienced cytokine release syndrome (CRS), a systematic inflammation response caused by cytokine release and can result in life-threatening toxicity. CAR T-cell therapy patients have to be closely monitored for CRS up to weeks, following a grading system based on vital signs and symptoms. However, there is still lacking a method to predict early onset of severe CRS or other toxicities with a high sensitivity and specificity. To this end, we are developed multiplexed, fast and ultrasensitive immunoassay platform to provide frequent high-dimensional cytokine profile data for managing CAR T-cell therapy and CRS mitigation.




Dr. Xin Zhao, PhD
Founder, CEO

Dr. Zhao is an expert in semiconductor device design, manufacturing, and characterization, receiving his Ph.D. from the Massachusetts Institute of Technology. With a keen interest to combine unique technology with business insights, he oversees Atantares’ strategy, fundraising, business development, and R&D.

Dr. Aniruddh Sarkar, PhD
Co Founder

Dr. Sarkar received his PhD in electrical engineering from the Massachusetts Institute of Technology, and also received training at Massachusetts General Hospital. He is an expert on blood processing technologies and bioMEMS/microfluidics.

Dr. Kumaran Kolandaivelu, MD, PhD
Co Founder

Dr. Kolandaivelu is trained in both engineering and medicine, having received a PhD in mechanical engineering at the Massachusetts Institute of Technology and M.D. from the Harvard Medical School. He trained at the Brigham and Women’s Hospital where he is a licensed cardiologist and an expert on the measurement of blood properties and translational assay development.


Dr. James E. Muller, MD

Founder, CEO of Infraredx, Inc.

Cardiologist, BWH

Dr. Andrew L. Frelinger, PhD

Assistant Professor, HMS

Assoc. Director, Center for Platelet Research Studies, BCH

Dr. Jonathan D. Gates, MD, MBA, FACS

System Director of Trauma, Hartford HealthCare